147 search results for: type 2 inflammation

<b>Type</b> <b>2</b> <b>Inflammation</b> Modulates the Neuroimmune Axis in PN

expert video

Type 2 Inflammation Modulates the Neuroimmune Axis in PN

12 min

Dermatology

Highlights from the WCD 2023 ADVENT symposium, examining how type 2 inflammation influences the neuroimmune axis in prurigo nodularis.

FeNO as a Biomarker for <b>Type</b> <b>2</b> Asthma

expert video

FeNO as a Biomarker for Type 2 Asthma

16 min

Pulmonology

Dr. Eugene Bleecker presents the utility of FeNO as a biomarker of type 2 inflammation, and its role in the disease burden of asthma.

CRSwNP: A Chronic <b>Type</b> <b>2</b> Inflammatory Disease

expert video

CRSwNP: A Chronic Type 2 Inflammatory Disease

2 min

Rhinology

Prof. Peter Hellings describes how type 2 inflammation drives CRSwNP.

How Does Protective <b>Type</b> <b>2</b> Immunity Become Harmful <b>Type</b> <b>2</b> <b>Inflammation</b>?

expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

4 min

Dermatology

In this video soundbite from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson explains how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation.

The Cycle of <b>Inflammation</b> in Adult Asthma

interactivity

The Cycle of Inflammation in Adult Asthma

5 min

Pulmonology

Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in asthma patients

Eosinophils as a Biomarker for <b>Type</b> <b>2</b> Asthma

expert video

Eosinophils as a Biomarker for Type 2 Asthma

15 min

Pulmonology

Dr. Elliot Israel presents the utility of eosinophils as a biomarker of type 2 inflammation and their role in the disease burden of asthma.

Inside the Hive: <b>Type</b> <b>2</b> Inflammatory Pathways in Chronic Spontaneous Urticaria

expert video

Inside the Hive: Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

16 min

Dermatology

Join Dr. Jason Hawkes in discussing the burden of CSU and how type 2 inflammation contributes to the development of chronic wheals (hives) and angioedema

Role of <b>Type</b> <b>2</b> <b>Inflammation</b> in Chronic Inflammatory Diseases

expert video

Role of Type 2 Inflammation in Chronic Inflammatory Diseases

15 min

Dermatology

Type 2 inflammatory mechanisms and key type 2 cytokines in the pathogenesis of atopic dermatitis – Presentation from the ADVENT symposium at ISID 2023

<b>Type</b> <b>2</b> <b>Inflammation</b> and Neuroimmune Axis Dysregulation in AD, PN, and CSU

expert video

Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU

3 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

Overview of <b>Type</b> <b>2</b> <b>Inflammation</b> in the Presentations of AD, PN, and CSU

expert video

Overview of Type 2 Inflammation in the Presentations of AD, PN, and CSU

2 min

Dermatology

Dr. Eric Simpson summarizes the role of type 2 inflammation in the clinical manifestations of AD, PN, and CSU.

videoanimation

The Pathophysiology of Prurigo Nodularis

5 min

Dermatology

An infographic exploring the pathophysiology of prurigo nodularis and the role of type 2 inflammation.

The Role of <b>Type</b> <b>2</b> <b>Inflammation</b> in Moderate-to-Severe AD

expert video

The Role of Type 2 Inflammation in Moderate-to-Severe AD

4 min

Dermatology

In this expert interview video focusing on topics from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Stephan Weidinger discusses how type 2 inflammation contributes to the systemic inflammation seen in patients with moderate-to-severe AD.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: JapanChange country/region